Skip to main content

Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans.

Publication ,  Journal Article
Carlson, D; Wang, R; Hastings, Z; Oliveira, LVN; Hester, MM; Rodriguez, N; Pedersen, GK; Tenor, JL; Perfect, JR; Specht, CA; Levitz, SM
Published in: J Fungi (Basel)
December 16, 2025

Infections with strains of the Cryptococcus neoformans species complex are responsible for over 100,000 deaths per year, predominantly due to meningitis in immunocompromised individuals. Despite much research, there are no licensed fungal vaccines available. Most experimental cryptococcal vaccine formulations have been tested in preclinical models using laboratory strains of C. neoformans, particularly H99 and KN99. However, to be effective, vaccines need to protect against the wide variety of cryptococcal isolates found worldwide, particularly in regions that have the highest burden of infections. Therefore, we explored vaccine-mediated protection of BALB/c mice against experimental cryptococcosis due to six C. neoformans strains originally isolated from patients with cryptococcal meningitis in Vietnam, Uganda, and Botswana. Two vaccines were tested: a live-attenuated C. neoformans vaccine lacking three chitin deacetylase genes, and a quadrivalent subunit protein vaccine adjuvanted with Cationic Adjuvant Formulation 01. When compared to unvaccinated mice, both vaccines provided significant protection against all six clinical strains. However, the degree of protection varied as a function of vaccine formulation and clinical strain. Lung leukocytes from vaccinated and infected mice had significantly increased antigen-stimulated interferon-gamma production compared with infected but unvaccinated mice. Thus, although the degree of protection varied, two cryptococcal vaccines significantly protected mice against experimental infection with cryptococcal strains representative of regions of the world that account for the majority of cryptococcal meningitis cases found globally. These data provide preclinical support for trialing vaccines in persons at high risk for developing cryptococcosis.

Duke Scholars

Published In

J Fungi (Basel)

DOI

EISSN

2309-608X

Publication Date

December 16, 2025

Volume

11

Issue

12

Location

Switzerland

Related Subject Headings

  • 3107 Microbiology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Carlson, D., Wang, R., Hastings, Z., Oliveira, L. V. N., Hester, M. M., Rodriguez, N., … Levitz, S. M. (2025). Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans. J Fungi (Basel), 11(12). https://doi.org/10.3390/jof11120886
Carlson, Diana, Ruiying Wang, Zachary Hastings, Lorena V. N. Oliveira, Maureen M. Hester, Nicolle Rodriguez, Gabriel Kristian Pedersen, et al. “Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans.J Fungi (Basel) 11, no. 12 (December 16, 2025). https://doi.org/10.3390/jof11120886.
Carlson D, Wang R, Hastings Z, Oliveira LVN, Hester MM, Rodriguez N, et al. Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans. J Fungi (Basel). 2025 Dec 16;11(12).
Carlson, Diana, et al. “Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans.J Fungi (Basel), vol. 11, no. 12, Dec. 2025. Pubmed, doi:10.3390/jof11120886.
Carlson D, Wang R, Hastings Z, Oliveira LVN, Hester MM, Rodriguez N, Pedersen GK, Tenor JL, Perfect JR, Specht CA, Levitz SM. Vaccine-Mediated Protection of Mice Against African and Asian Clinical Strains of Cryptococcus neoformans. J Fungi (Basel). 2025 Dec 16;11(12).

Published In

J Fungi (Basel)

DOI

EISSN

2309-608X

Publication Date

December 16, 2025

Volume

11

Issue

12

Location

Switzerland

Related Subject Headings

  • 3107 Microbiology